Perfusate hemoglobin during normothermic liver machine perfusion as biomarker of early allograft dysfunction: A pilot study

Akinori Maeda,Graham Starkey,Sofia Spano,Anis Chaba,Glenn Eastwood,Osamu Yoshino,Marcos Vinicius Perini,Michael Fink,Rinaldo Bellomo,Robert Jones

DOI: https://doi.org/10.1111/aor.14862

2024-09-20

Artificial Organs

Abstract:Perfusate hemoglobin levels decrease during normothermic machine perfusion and were associated with postoperative early allograft dysfunction or transaminase levels of recipients. Future studies to validate the findings from this pilot study are warranted. Background Normothermic machine perfusion (NMP) aims to reduce ischemia–reperfusion injury in donor livers and its clinical manifestation, early allograft dysfunction (EAD) by maintaining perfusion and oxygenation. However, there is limited data on which NMP perfusate biomarkers might be associated with such EAD and the role of perfusate hemoglobin has not been assessed. Methods We performed a pilot retrospective analysis of adult donor livers undergoing NMP between 2020 and 2022 at our center. NMP was commenced at the recipient hospital after initial static cold storage. All NMP circuits were primed in the same manner according to the manufacturer's instructions. Livers were stratified by initial perfusate hemoglobin below (≤5.2 mmol/L) or above (>5.2 mmol/L) the median. The association between hemoglobin levels and EAD or recipient peak transaminase levels was assessed. Results Among 23 livers, eight were considered unsuitable for transplantation, leaving 15 livers for assessment. Higher initial hemoglobin was associated with a lower risk of EAD (0% vs. 55.6%, p = 0.04). Perfusate hemoglobin decreased after NMP initiation (p = 0.003) and negatively correlated with recipient peak transaminase levels (ALT: ρ = −0.72, p = 0.002; AST: ρ = −0.79, p

engineering, biomedical,transplantation